AstraZeneca PLC
featured
Patent expirations on big-name drugs has resulted in modestly less spending on medicines in the U.S. for the first time in at least 55 years, a report showed Thursday.
» Read More
More
-
HAYWARD, Calif.-- Impax Laboratories Inc. said Friday it is now selling a generic version of the migraine drug Zomig. Impax is now selling a low-cost generic version of Zomig tablets and orally disintegrating Zomig tablets in two strengths. Impax gets the profits from U.S. sales of Zomig and makes royalty payments to AstraZeneca.
-
NEW YORK, May 15- Before Optimer Pharmaceuticals Inc even put itself up for sale earlier this year, Cubist Pharmaceuticals Inc offered to buy the antibiotic maker for $20 per share, or nearly $1 billion, two people familiar with the matter told Reuters on Wednesday.
-
Companies like Pfizer Inc and AstraZeneca have grown dependent on higher U.S. prices to generate profits as generic rivals to their best-selling medicines enter the world market, Europe's government-run health plans clamp down on spending and sales growth in emerging markets stutters.
-
YORK, Pa.-- Dentsply International Inc. said Thursday its net income rose 35 percent in the first quarter, but the dental products company lowered its estimates for the full year. Shares of Dentsply lost $1.89, or 4.3 percent, to $42.31 in midday trading. Costs related to the $1.79 billion deal weighed on Dentsply's first-quarter results in 2012..
-
Patent expirations on big-name drugs has resulted in modestly less spending on medicines in the U.S. for the first time in at least 55 years, a report showed Thursday.
-
*Sanofi turns ex-dividend, weighs on France's CAC 40. "We're seeing excessive optimism, with more and more retail investors turning bullish, which is never a good sign," said Guillaume Dumans, co-ahead of 2 Bremans, a Paris- based research firm using behavioural finance to monitor investor sentiment.
-
PARIS, May 9- European shares fell in early trade on Thursday, halting a sharp three-week rally to multi-year highs, with pharmaceutical stocks trimming recent lofty gains. GlaxoSmithKline and AstraZeneca were both down 0.5 percent.
-
May 9- Patent expirations on big-name drugs such as Lipitor and Plavix has resulted in modestly less spending on medicines in the United States for the first time in at least 55 years, according to a report released on Thursday.
-
After approvals last year from the FDA for 39 novel medicines- a record only beaten in 1996- the healthy pace has continued into 2013.. And drugmakers are getting further help from a new FDA program to accelerate life-saving therapies designated as a "breakthrough," opening to door to earlier approval based on quicker studies, where clinical data is compelling.
-
May 6- Astrazeneca Pharma India Ltd:. *Promoter has decided to pay financial grant of 1.19 billion rupees to 1.40. *Says first tranch of 740 million rupees to be provided to co in current.
-
FRANKFURT, May 3- Eli Lilly, the world's fourth-largest diabetes drugs maker, aims to have the widest range of anti diabetic drugs in order to win a larger slice in the growing market.
-
*Aiming to win bigger slice of growing market* Lilly currently No.4 in $40 bln diabetes market* Lilly says mainly addressing GPs, not specialists By Ludwig Burger and Frank Siebelt. FRANKFURT, May 3- Eli Lilly, the world's fourth-largest diabetes drugs maker, aims to have the widest range of anti diabetic drugs in order to win a larger slice in the growing market.
-
*Pfizer, Amgen, AstraZeneca among firms placing bets. LONDON, May 3- Is nanomedicine the next big thing? Three deals struck this year by privately held Bind Therapeutics, together worth nearly $1 billion if experiments are successful, highlight a new interest in using such tiny carriers to deliver drug payloads to specific locations in the body.
-
*Pfizer, Amgen, AstraZeneca among firms placing bets. LONDON, May 3- Is nanomedicine the next big thing? Three deals struck this year by privately held Bind Therapeutics, together worth nearly $1 billion if experiments are successful, highlight a new interest in using such tiny carriers to deliver drug payloads to specific locations in the body.
-
The Pleasanton, California- based company has hired Morgan Stanley and Deutsche Bank AG, the sources said on Tuesday. Veeva Systems, Morgan Stanley and Deutsche Bank declined to comment. It has more than 150 customers including large pharmaceutical companies like AstraZeneca PLC, Bayer, Eli Lilly& Co.
-
For a summary of rating actions and price target changes on European companies: Reuters Eikon users, click on RCH/ EUROPE Reuters 3000 Xtra users, double-click RCH/ EUROPE Reuters Station users, click. 1580.
-
*Morgan Stanley raises target price to 3400 p from 3310 p; rating euqal weight. For a summary of rating actions and price target changes on European companies:. Reuters Station users, click. 1580.
-
For a summary of rating actions and price target changes on European companies: Reuters Eikon users, click on RCH/ EUROPE Reuters 3000 Xtra users, double-click RCH/ EUROPE Reuters Station users, click. 1580.
-
*Deutsche Bank raises price target to 3160 p from 3100 p. For a summary of rating actions and price target changes on European companies:. Reuters Station users, click. 1580.
-
*AstraZeneca PLC: Bernstein cuts price target to 3474 p from 3563 p; rating market perform. *Astrazeneca: Bernstein cuts price target to $53 from $54; rating. Reuters Station users, click. 1568.